- Home
- BMEA vs SRZN Comparison
BMEA vs SRZN Comparison
Compare BMEA & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- SRZN
- Stock Information
- Founded
- BMEA 2017
- SRZN 2015
- Country
- BMEA United States
- SRZN United States
- Employees
- BMEA 63
- SRZN N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- BMEA Health Care
- SRZN Health Care
- Exchange
- BMEA Nasdaq
- SRZN Nasdaq
- Market Cap
- BMEA 96.9M
- SRZN 120.0M
- IPO Year
- BMEA 2021
- SRZN N/A
- Fundamental
- Price
- BMEA $1.36
- SRZN $12.17
- Analyst Decision
- BMEA Strong Buy
- SRZN Strong Buy
- Analyst Count
- BMEA 7
- SRZN 2
- Target Price
- BMEA $8.86
- SRZN $38.50
- AVG Volume (30 Days)
- BMEA 1.7M
- SRZN 39.7K
- Earning Date
- BMEA 11-04-2025
- SRZN 11-07-2025
- Dividend Yield
- BMEA N/A
- SRZN N/A
- EPS Growth
- BMEA N/A
- SRZN N/A
- EPS
- BMEA N/A
- SRZN N/A
- Revenue
- BMEA N/A
- SRZN $3,604,000.00
- Revenue This Year
- BMEA N/A
- SRZN N/A
- Revenue Next Year
- BMEA N/A
- SRZN N/A
- P/E Ratio
- BMEA N/A
- SRZN N/A
- Revenue Growth
- BMEA N/A
- SRZN N/A
- 52 Week Low
- BMEA $1.22
- SRZN $5.90
- 52 Week High
- BMEA $8.99
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- BMEA 40.15
- SRZN 34.13
- Support Level
- BMEA $1.22
- SRZN $11.39
- Resistance Level
- BMEA $1.35
- SRZN $14.38
- Average True Range (ATR)
- BMEA 0.10
- SRZN 0.58
- MACD
- BMEA 0.00
- SRZN -0.26
- Stochastic Oscillator
- BMEA 31.16
- SRZN 20.27
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).